That Pricey New Alzheimer’s Drug? Still Not Great

We really need good treatments for Alzheimer’s. But Biogen’s very expensive (and maybe not very effective) drug Aduhelm is not the treatment we’re looking for. Today we look at the saga of Adulhelm’s approval and its road to acceptance (or lack thereof) in the medical community.


Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on email

Hidden information below


* indicates required
Email Format